英国尿液标本分离肠杆菌目细菌碳青霉烯耐药及碳青霉烯酶产生率:英国感染-碳青霉烯耐药评估监测试验(iCREST-UK)结果
iCREST-UK研究在英国五家诊断实验室对7504份尿液标本中革兰阴性菌生长物筛查碳青霉烯酶-producing肠杆菌目(CPE),22株疑似CPE中10株经PCR确认携带NDM(5株)、IMP(2株)、KPC(2株)或OXA-48-like(1株)碳青霉烯酶,确认CPE频率为0.13%(10/7504)。本地检测的头孢他啶/阿维巴坦MIC与中心微量肉汤法结果分类完全一致,7株头孢他啶/阿维巴坦耐药(MIC≥256 mg/L)菌株均产NDM或IMP金属β-内酰胺酶。
要点
- 确认CPE在革兰阴性尿分离株中频率低,为0.13%(10/7504),但五家参与中心均有发现。
- 检测到的碳青霉烯酶基因多样性反映英国CPE复杂流行病学。
- 7株头孢他啶/阿维巴坦耐药(MIC≥256 mg/L)菌株均产NDM或IMP金属β-内酰胺酶。
核心结论
- 确认CPE在革兰阴性尿分离株中频率低,为0.13%(10/7504),但五家参与中心尿液标本中均发现CPE,且碳青霉烯酶基因多样性反映英国CPE复杂流行病学。
- 这些数据可为地方政策提供信息,用于评估对尿液标本革兰阴性菌常规检测碳青霉烯类作为患者管理和/或感染预防控制策略一部分的成本效益和临床价值。
研究设计与样本
- 在英国五家诊断实验室对常规尿液标本中革兰阴性菌生长物进行碳青霉烯酶-producing肠杆菌目(CPE)筛查,每家实验室最多2000份标本。
- 将阳性生长物接种于chromID® CARBA SMART琼脂,疑似CPE菌落经Etest检测美罗培南和头孢他啶/阿维巴坦敏感性,并送至中心实验室进行PCR确认CPE状态和微量肉汤MIC测定。
主要发现
- 从7504份尿液标本中鉴定出22株疑似CPE。
- 10株经PCR确认携带NDM(5株)、IMP(2株)、KPC(2株)或OXA-48-like(1株)碳青霉烯酶。
- 本地检测的头孢他啶/阿维巴坦MIC与中心微量肉汤法测定结果分类完全一致。
- 7株头孢他啶/阿维巴坦耐药菌株(MIC≥256 mg/L)均产NDM或IMP金属β-内酰胺酶。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Although carbapenem susceptibility testing has been recommended for all Enterobacteriaceae from clinical specimens, for practical reasons a carbapenem is not included in many primary antibiotic panels for urine specimens. The 'iCREST' study sought carbapenemase-producing Enterobacteriaceae (CPE) in routine urine specimens yielding Gram-negative growth in five diagnostic laboratories in the UK. We sought also to compare locally and centrally determined MICs of meropenem and ceftazidime/avibactam. METHODS: Positive growth from up to 2000 urine specimens per laboratory was plated onto chromID® CARBA SMART agar. Suspected CPE colonies were tested locally by Etest for susceptibility to meropenem and ceftazidime/avibactam, and referred to central laboratories for PCR confirmation of CPE status and microbroth MIC determination. RESULTS: Twenty-two suspected CPE were identified from 7504 urine specimens. Ten were confirmed by PCR to have NDM (5), IMP (2), KPC (2) or OXA-48-like (1) carbapenemases. Locally determined ceftazidime/avibactam MICs showed complete categorical agreement with those determined centrally by microbroth methodology. The seven ceftazidime/avibactam-resistant isolates (MICs ≥256 mg/L) had NDM or IMP metallo-carbapenemases. CONCLUSIONS: The frequency of confirmed CPE among Gram-negative urinary isolates was low, at 0.13% (10/7504), but CPE were found in urines at all five participating sites and the diversity of carbapenemase genes detected reflected the complex epidemiology of CPE in the UK. These data can inform local policies about the cost-effectiveness and clinical value of testing Gram-negative bacteria from urine specimens routinely against a carbapenem as part of patient management and/or infection prevention and control strategies.
引用
- Woodford N, Xu-McCrae L, Mushtaq S, et al. Prevalence of carbapenem resistance and carbapenemase production among Enterobacteriaceae isolated from urine in the UK: results of the UK infection-Carbapenem Resistance Evaluation Surveillance Trial (iCREST-UK). J Antimicrob Chemother. 2018. PMID: 29253163. doi:10.1093/jac/dkx471
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。